Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 2/20 | 1.00 |
| ▸ | SYK | P43405 | 2/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 1.00 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 0.65 |
| ▸ | FER | P16591 | 1/20 | 0.65 |
| ▸ | FRK | P42685 | 1/20 | 0.65 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.65 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30273130 | 1.00 | TYK2 (1.00) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL31025329 | 1.00 | TYK2 (1.00) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL23326603 | 0.87 | TYK2 (0.76) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL3355321 | 0.86 | TYK2 (0.76) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL3110596 | 0.86 | TYK2 (0.75) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL11929833 | 0.84 | TYK2 (0.72) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL30273129 | 0.84 | TYK2 (0.72) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL1617807 | 0.84 | TYK2 (0.72) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL12634088 | 0.83 | TYK2 (0.70) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL18115397 | 0.83 | TYK2 (0.85) | TYK2SYKIRAK4BRSK1FES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113683596-B | Pyrimidine tankyrase 2 inhibitor and preparation method and application thereof | 上海应用技术大学 | 2023-02-10 | — | — | CN | claimed |
| CN-113683596-A | Pyrimidine tankyrase 2 inhibitor and preparation method and application thereof | 上海应用技术大学 | 2021-11-23 | — | — | CN | claimed |
| CN-113683596-B | Pyrimidine tankyrase 2 inhibitor and preparation method and application thereof | 上海应用技术大学 | 2023-02-10 | — | — | CN | disclosed |
| CN-113683596-A | Pyrimidine tankyrase 2 inhibitor and preparation method and application thereof | 上海应用技术大学 | 2021-11-23 | — | — | CN | disclosed |
| US-20180271873-A1 | METHODS FOR TREATING VIRAL INFECTIONS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2018-09-27 | — | — | US | disclosed |
| WO-2016161176-A1 | METHODS FOR TREATING VIRAL INFECTIONS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161176-A1 | METHODS FOR TREATING VIRAL INFECTIONS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-10-06 | — | — | WO | disclosed |
| US-7923557-B2 | Process for preparing trisubstituted pyrimidine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923557-B2 | Process for preparing trisubstituted pyrimidine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923557-B2 | Process for preparing trisubstituted pyrimidine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20060122209-A1 | Process for preparing trisubstituted pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2006053112-A1 | PROCESS FOR PREPARING TRISUBSTITUTED PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122209-A1 | Process for preparing trisubstituted pyrimidine compounds | TYMS, NUDT1, TYMP | TYK2 1701/4885SYK 1920/4885IRAK4 3254/4885 |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | BRCA1, VHL, ESR1 | TYK2 2409/4885SYK 3624/4885IRAK4 2390/4885 |
| US-20180271873-A1 | METHODS FOR TREATING VIRAL INFECTIONS | HAVCR2, CCL11, EIF2AK2 | TYK2 3663/4885SYK 2919/4885IRAK4 736/4885 |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | BRCA1, VHL, ESR1 | TYK2 2409/4885SYK 3624/4885IRAK4 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.